Paroxysmal Nocturnal Hemoglobinuria (PNH) Clinical Trial
Official title:
CONSENT II: Coversin in Paroxysmal Nocturnal Hemoglobinuria (PNH) in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms
Coversin in Paroxysmal Nocturnal Hemoglobinuria (PNH) in patients with resistance to Eculizumab due to complement C5 polymorphisms.
Coversin, a small protein complement C5 inhibitor which prevents the cleavage of C5 by C5 convertase into C5a and C5b, will be used in an open label, non-comparative clinical trial in patients with PNH and proven resistance to eculizumab due to C5 polymorphisms. Patients will be treated with Coversin by daily subcutaneous injection for 6 months in order to determine the safety and efficacy of the drug in these circumstances. If satisfactory control of the PNH is achieved, and at the discretion of the Principal Investigator (PI), patients will have the option of remaining on Coversin and being entered into the long term follow-up study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00004143 -
Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
|
Phase 2 | |
| Terminated |
NCT05116787 -
BCX9930 for the Treatment of PNH in Subjects Not Receiving Other Complement Inhibitor Therapy
|
Phase 2 | |
| Recruiting |
NCT06294301 -
A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants
|
Phase 1 | |
| Completed |
NCT03472885 -
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab
|
Phase 2 | |
| Completed |
NCT03946748 -
Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
| Completed |
NCT03078582 -
Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients
|
Phase 2 | |
| Completed |
NCT03053102 -
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
| Not yet recruiting |
NCT06312644 -
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
|
||
| Completed |
NCT03588026 -
Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576
|
Phase 3 | |
| Completed |
NCT03056040 -
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
|
Phase 3 | |
| Completed |
NCT00145613 -
Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies
|
Phase 2 | |
| Completed |
NCT00587054 -
Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders
|
Phase 2 | |
| Recruiting |
NCT05876312 -
Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
|
Phase 1 | |
| Completed |
NCT04820530 -
Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy
|
Phase 3 | |
| Terminated |
NCT03225287 -
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
|
Phase 2 | |
| Completed |
NCT04558918 -
Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
|
Phase 3 | |
| Completed |
NCT02352493 -
A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04901936 -
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
| Completed |
NCT02264639 -
A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH
|
Phase 1 | |
| Recruiting |
NCT03520647 -
Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
|
Phase 2 |